• The Saudi pharma market is the largest across the MENA region with a market size of US$7.5 billion with a growth expected at a CAGR of around 5.5% according to experts

Abu Dhabi, United Arab Emirates: The importance of Saudi Arabia’s pharmaceutical industry in delivery of the country’s 2030 Vision was highlighted at CPhI Middle East & Africa, currently taking place at the Abu Dhabi National Exhibition Centre (ADNEC) from 16-18 September.

During a presentation by Dr Faisal BinDail, Chairman of the National Committee for Pharmaceutical Industries, titled Delivering Saudi Arabia’s Vision 2030, a range of topics related to the pharmaceutical industry were discussed, including incentives for stimulating local manufacturing and the opportunities the emerging contract manufacturing sector present.

Dr. BinDail said: “In the context of Saudi Arabia, Pharma manufacturing holds an important position in achieving the Kingdom’s Vision 2030. The regulatory body, local industry players, global companies have realised the importance of this initiative and are working towards strengthening of localised Pharmaceutical manufacturing. Part of the transformation plan in the kingdom is to raise the percentage of total pharmaceutical production to 40% from the current 20%. The Government is supportive, local companies are gearing up and the regulatory body is encouraging, facilitating and providing incentives – thereby encouraging global companies to take advantage of this opportunity.

“Moreover, there is an enthusiasm among the local players to raise their standards and provide quality affordable medicines. Saudi Arabia is one of the few countries to adopt track and trace system to curb the menace of counterfeit.”

Saudi Arabia is the largest pharmaceutical market in the MENA region worth US$7.5 billion dollars and is expected to grow at a CAGR of around 5.5%.

“The market is dominated by branded products, as there is a preference for brands locally, but at the same time there is an opportunity for generics as well to expand. Around 20% of the Pharma market is locally manufactured, while 80% is still imported from different countries, from the US, Europe, and different parts of the world, this is in brief how the Pharmaceutical market in Saudi Arabia currently looks like,” added Dr. BinDail.

CPhI Middle East and Africa, which was officially opened by His Excellency Sheikh Nahyan bin Mubarak al Nahyan, Minister of Tolerance, is set to close tomorrow, Wednesday 18th September. Sponsored by the Ministry of Health and Protection (MoHaP), CPhI is attracting attendees from the Middle East and Africa (MEA) - of which the MENA region accounts for 4% of the global pharma market. The event is providing a showcase for over 290 exhibitors and is expected to attract more than 4,900 pharma professionals from around the world.

-Ends- 

About CPhI

CPhI drives growth and innovation at every step of the global pharmaceutical supply chain from drug discovery to finished dosage. Through exhibitions, conferences and online communities, CPhI brings together more than 100,000 pharmaceutical professionals each year to network, identify business opportunities and expand the global market. CPhI hosts events in Europe, North America, Korea, China, India, Japan, Southeast Asia and the Middle East, and co-locates with ICSE for contract services, P-MEC for machinery, equipment & technology, FDF for finished dosage formulations, InnoPack for pharmaceutical packaging and BioPh for biopharma. CPhI provides an online buyer & supplier directory at CPhI-Online.com.

For more information visit: www.cphi.com 

About Informa Markets

Informa Markets creates platforms for industries and specialist markets to trade, innovate and grow. Our portfolio is comprised of more than 550 international B2B events and brands in markets including Healthcare & Pharmaceuticals, Infrastructure, Construction & Real Estate, Fashion & Apparel, Hospitality, Food & Beverage, and Health & Nutrition, among others. We provide customers and partners around the globe with opportunities to engage, experience and do business through face-to-face exhibitions, specialist digital content and actionable data solutions. As the world’s leading exhibitions organiser, we bring a diverse range of specialist markets to life, unlocking opportunities and helping them to thrive 365 days of the year. For more information, please visit www.informamarkets.com.  

Media contact
JAMES LAKIE
General Manager
Tel: +971 4 365 2711 | Mobile: +971 50 153 6544
E-mail: james.lakie@shamalcomms.com
Office 106, Arjaan Office Tower, Dubai Media City
PO Box 502701 | Dubai, United Arab Emirates
Website: www.shamalcomms.com     

A member of the WorldWisePR Affiliates

© Press Release 2019

Disclaimer: The contents of this press release was provided from an external third party provider. This website is not responsible for, and does not control, such external content. This content is provided on an “as is” and “as available” basis and has not been edited in any way. Neither this website nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this press release.

The press release is provided for informational purposes only. The content does not provide tax, legal or investment advice or opinion regarding the suitability, value or profitability of any particular security, portfolio or investment strategy. Neither this website nor our affiliates shall be liable for any errors or inaccuracies in the content, or for any actions taken by you in reliance thereon. You expressly agree that your use of the information within this article is at your sole risk.

To the fullest extent permitted by applicable law, this website, its parent company, its subsidiaries, its affiliates and the respective shareholders, directors, officers, employees, agents, advertisers, content providers and licensors will not be liable (jointly or severally) to you for any direct, indirect, consequential, special, incidental, punitive or exemplary damages, including without limitation, lost profits, lost savings and lost revenues, whether in negligence, tort, contract or any other theory of liability, even if the parties have been advised of the possibility or could have foreseen any such damages.